Chugai Ups Forecast On Star Performer Hemlibra
Executive Summary
Roche affiliate substantially raises full-year forecast following double-digit sales and profit growth, mainly on the back of strength for hemophilia drug Hemlibra.
You may also be interested in...
Chugai To Plow $1bn+ Into New Core R&D Site
Japanese firm unveils major restructuring of R&D sites in Japan through a new $1bn core lab set to open in early 2023 and the closure of two other long-established facilities.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.